[ACST] Acasti Pharma, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization: 14.14 M
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For ACST
ACST is in the long-term down -98% below S&P in 9 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Acasti Pharma Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of therapies for abnormalities in blood lipids, and the treatment and prevention of various cardiometabolic disorders in Canada and the United States. The company offers Onemia, a medical food that is used in the dietary management of illnesses associated with omega-3 phospholipids deficiency related to cardiometabolic disorders. Its product development pipeline includes CaPre, a drug product candidate that is in Phase II clinical trials for the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. Acasti Pharma Inc. is a subsidiary of Neptune Technologies & Bioressources Inc.
See how to gain 20% in 14 sec with TrendsInvesting
Fundamental Ratios
| Shares Outstanding | 10.71 M | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | |||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | Sales Growth - Q/Q | P/E | ||||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | ROE | ROI | ||||
| Current Ratio | Quick Ratio | Long Term Debt/Equity | Debt Ratio | ||||
| Gross Margin | Operating Margin | Net Profit Margin | Dividend Payout Ratio | ||||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | Cash From Investing Activities | Cash From Operating Activities | Gross Profit | ||||
| Net Profit | Operating Profit | Total Assets | Total Current Assets | ||||
| Total Current Liabilities | Total Debt | Total Liabilities | Total Revenue |
Technical Data
| High 52 week | 3.1 | Low 52 week | 0.63 | Last close | 0.71 | Last change | 1.59% |
| RSI | 36.35 | Average true range | 0.04 | Beta | 0.3 | Volume | 4.94 M |
| Simple moving average 20 days | -2.49% | Simple moving average 50 days | -23.16% | Simple moving average 200 days | -39.8% |
Performance Data
| Performance Week | 7.92% | Performance Month | -34.26% | Performance Quart | -31.73% | Performance Half | -44.96% |
| Performance Year | -43.2% | Performance Year-to-date | -24.69% | Volatility daily | 6.55% | Volatility weekly | 14.65% |
| Volatility monthly | 30.03% | Volatility yearly | 104.04% | Relative Volume | 5202.7% | Average Volume | 196.58 K |
| New High | New Low |
News
2019-01-09 11:58:00 | 4 Healthcare Stocks Looking To Set January Highs
2019-01-09 08:00:00 | Acasti Pharma Awarded Broad Composition-of-Matter and Method of Use Patents by the European Patent Office
2018-12-28 09:55:02 | Generic Industry on Path to Recovery: 3 Hot Picks for 2019
2018-12-20 08:00:00 | Acasti Pharma Achieves Planned Enrollment Targets for TRILOGY Phase 3 Trials of CaPre® in Patients with Severe Hypertriglyceridemia
2018-11-27 07:00:00 | Acasti Pharma to Present at the 11th Annual LD Micro Main Event
2018-11-14 08:53:13 | Acasti: Fiscal 2Q Earnings Snapshot
2018-11-14 08:00:00 | Acasti Pharma Provides Business Update for Second Quarter of Fiscal 2019
2018-11-07 08:00:00 | Acasti Pharma Schedules Second Quarter Fiscal 2019 Conference Call
2018-10-23 09:00:11 | Acasti Pharma Announces Closing of C$27.6 Million Underwritten Public Offering of Common Shares Including the Exercise of the Over-Allotment Option
2018-10-11 07:30:00 | Acasti Pharma Announces Closing of $19.1 Million Underwritten Public Offering of Common Shares
2018-10-10 08:05:00 | Acasti Pharma Looks Toward Phase III for CaPre with Recent Financing, Analysts Review
2018-10-04 09:35:40 | Acasti Pharma Announces Pricing of $16.6 Million Underwritten Public Offering of Common Shares
2018-10-04 07:59:50 | The Daily Biotech Pulse: AtriCure's Guidance, Guardant Health And Kodiak To Debut
2018-10-03 16:23:12 | Acasti Pharma Announces Public Equity Offering
2018-10-03 16:23:11 | Acasti Pharma Announces Proposed Underwritten Public Offering of Common Shares
2018-10-02 09:10:25 | The Daily Biotech Pulse: TransEnterix's Positive Pre-Announcement, Merit Medical Opens Wallet, GW Pharma To Offer ADS Shares
2018-10-01 17:00:00 | Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
2018-09-28 08:17:00 | Today’s Research Reports on Stocks to Watch: Achieve Life Sciences and Acasti Pharma
2018-09-24 08:00:00 | Acasti Pharma Appoints Jean-François Boily as Vice President of Finance
2018-09-18 08:52:02 | Acasti Pharma Provides Clinical and Market Update
2018-08-29 16:05:00 | Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM
2018-08-14 13:00:00 | Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2019
2018-08-14 08:39:31 | Acasti: 2Q Earnings Snapshot
2018-07-31 17:09:05 | Acasti Pharma Announces Mailing of Management Information Circular and Amendment to Stock Option Plan
2018-07-24 09:15:11 | Benzinga Pro's 5 Stocks To Watch Today
2018-07-24 07:00:00 | Acasti Pharma Awarded Composition-of-Matter Patent by the U.S. Patent and Trademark Office
2018-07-02 17:00:00 | Acasti Pharma Announces Annual Performance Grants of Stock Options, Amendment of Stock Option Plan and Issuance of Common Shares in Payment of Outstanding Interest under Debentures
2018-06-28 08:26:54 | Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut
2018-06-27 17:00:00 | Acasti Pharma Business Update for the Fourth Quarter and Fiscal 2018
2018-06-11 20:07:54 | Acasti Pharma Reports on Positive Feedback Following Today’s Presentation at the XVIII International Symposium on Atherosclerosis
2018-06-06 07:00:00 | Acasti Pharma to Present at the XVIIIth International Symposium on Atherosclerosis
2018-06-04 07:00:00 | Acasti Pharma Appoints Brian Groch as Chief Commercial Officer
2018-05-18 07:00:00 | Acasti Pharma Retains Crescendo Communications for Investor Relations Services in the United States
2018-05-14 13:23:16 | Acasti Pharma Announces Full Exercise of Over-Allotment Option
2018-05-09 12:42:27 | Acasti Pharma Announces Closing of $10 Million Underwritten Offering
2018-04-27 08:00:00 | Acasti Pharma Appoints Donald Olds to its Board of Directors and Audit Committee
2018-04-24 12:17:36 | Acasti Pharma Prices $10 Million Underwritten Offering
2018-04-23 16:11:03 | Acasti Pharma Announces Overnight Marketed Public Unit Offering
2018-04-02 08:00:00 | Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
2018-03-14 08:00:00 | Acasti Pharma Announces First Patient Randomized in Pivotal TRILOGY Phase 3 Program of CaPre in Severe Hypertriglyceridemia
2018-02-14 05:01:15 | Acasti reports 4Q loss
2018-02-13 17:00:00 | Acasti Pharma Reports Third Quarter FY 2018 Financial Results
2018-01-22 17:05:00 | Acasti Pharma Announces the Closing of Over-Allotment Option for its Public Offering of Common Shares
2018-01-16 08:00:00 | Acasti Pharma Announces Change to Board of Directors
2018-01-08 07:00:00 | Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest Under Debentures
2018-01-04 08:00:00 | Acasti Expands Global Patent Portfolio with Newly Granted Patents in South Korea and Canada
2018-01-02 17:05:00 | Dawson James Securities Announces Closing of US $10 Million Firm Commitment Offering of Common Shares and Warrants for Acasti Pharma Inc.
2018-01-02 08:00:00 | Acasti Pharma to Present at Biotech Showcase Conference
2018-01-02 07:50:00 | Wired News – Acasti Closes $10 Million Common Share Offering, Intends to Use the Proceeds for Scaling Development of CaPre